Is IDORSIA AG REGISTERED SHARES SWITZERLAN (OTCMKTS:IDRSF) a Buy? The Stock Reported more Sellers

The stock of IDORSIA AG REGISTERED SHARES SWITZERLAN (OTCMKTS:IDRSF) registered an increase of 5.99% in short interest. IDRSF’s total short interest was 1.22M shares in September as published by FINRA. Its up 5.99% from 1.15M shares, reported previously. With 900 shares average volume, it will take short sellers 1357 days to cover their IDRSF’s short positions.

It closed at $25.21 lastly. It is up 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.

Actelion Ltd, Drug Discovery Operations and Early-Stage Clinical Development Assets develops ACT-132577 antagonist and provides related clinical development services and is located in Switzerland. The company has market cap of $3.30 billion.

More recent Idorsia Ltd (OTCMKTS:IDRSF) news were published by: Investorplace.com which released: “The 10 Best Acquisitions of 2017 – Investorplace.com” on November 29, 2017. Also Seekingalpha.com published the news titled: “Idorsia AG 2017 Q4 – Results – Earnings Call Slides – Seeking Alpha” on February 07, 2018. Seekingalpha.com‘s news article titled: “Idorsia: A Swiss Biotech Poised For Fantastic Growth – Seeking Alpha” with publication date: July 16, 2019 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.